Answers are grounded in this paper and cite their sources.
Materials and MethodsThree CAP EPT surveys (MX-1 A, B, C) for HLA class I and (MX-2 A, B and C) for HLA class II, comprising of four samples for HLA -class I, two samples for HLA -class II were processed during the period January -December 2014.Lifecodes Screen & identification kits were used for antibody screening and specification.Lifecodes DSA kits were used for Luminex crossmatch.All kits were purchased from Immucor, India.The protocol mentioned in the product insert was followed for performing the tests and MATCH ITI Antibody software was used for analysis.All EQAS samples were stored as per specification (2-80 Celsius) until processing which was done within 72 hrs of receipt.A positive or negative assignment was made on the basis of both mean fluorescence intensity (MFI) and score which incorporates a correction for the background.MFI > 500 was assigned positive only if the score was > two.This was followed for all three antibody detection assays.The results obtained were compared with that of Flowcytometry results provided in CAP survey for concordance.Flowcytometry identified more antibodies than Luminex for all samples and in one class I sample specification was different from Luminex although Luminex is known to be more sensitive [2].Anti DQA1 and anti DPB1 antibodies were not included in this analysis as the kit is known not to detect them.Higher PRA of sample was associated with greater number of antibodies and a concomitant increase in specificities not identified by Luminex.Performance in EQAS was satisfactory because results for first 16
No takes yet. Share an insight, caveat, or question.
Mishra et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: